Wall Street Journal - Sept 27
Sept 27 (Reuters) -The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
- U.S. antitrust enforcers are set to bar Hess HES.N CEO John Hess from joining the board of Chevron CVX.N as part of a deal to approve a $53 billion tie-up between Hess and Chevron.
- Accident investigators with the National Transportation Safety Board on Thursday urged the Federal Aviation Administration and Boeing BA.N to address a potential hazard on about 350 of Boeing's 737 models currently flying.
- DirecTV is in advanced talks to acquire its satellite-TV rival Dish DISH.MX and a deal could be finalized as soon as Monday.
- The U.S. FDA approved Bristol-Myers Squibb's BMY.N schizophrenia drug Cobenfy, also known as KarXT, on Thursday.
- Alzheimer's drug developer Cassava Sciences SAVA.O on Thursday agreed to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for its drug Simufilam.
- Newsmax said it has settled a lawsuit brought by Smartmatic over false claims that the voting-technology company helped rig the 2020 presidential election.
(Compiled by Bengaluru newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
